Summary
Biocides (antiseptics and disinfectants) are widely used in hospitals and pharmaceutical industries for contamination control. The emergence of reduced susceptibility to biocides is the major concern and this is caused by various factors, among which plasmid-mediated resistance is common. Many publications describe the antibiotic resistance and mechanisms in a clinical setting. However, there are only limited studies available worldwide addressing the molecular mechanisms of biocide resistance in the pharmaceutical sector. In addition, there is a considerable lack of scientific reports regarding minimum inhibitory concentration (MIC) values of typical biocides against pharmaceutical cleanroom environmental isolates. This review analyses the plasmid-mediated resistance in typical pharmaceutical micro-organisms and prevalence of biocide-resistant genes among common clinical and pharmaceutical isolates. This review discusses the MIC values of biocides in pharmaceutical environmental isolates, indicating the importance of the correlation between the presence or absence of biocide-resistant genes and reduced susceptibility of MIC values. This review recommends that pharmaceutical organizations adopt policies and test methodologies to examine the MICs of common cleanroom biocides against the most common types of cleanroom environmental isolates.
Introduction
Biocides, including antiseptics and disinfectants, have been used extensively in hospitals and in the pharmaceutical industry for the disinfection of various medical devices and to reduce environmental bioburden in cleanrooms and controlled environments (Sandle 2016) . The widespread usage of products containing low concentrations of commonly used biocides, such as phenolics and quaternary ammonium compounds (QACs), raises the subject of their efficacy and it additionally raises concerns about the possible emergence of microbial resistance (Daschner and Schuster 2004; Russell 2004; Thomas et al. 2005) . Microbial resistance to biocides may be an intrinsic property or it may arise either by chromosomal gene mutation or by the acquisition of genetic material in the form of plasmids or transposons (Russell 2001) . The emergence of microbial resistance to biocides may lead to a failure in disinfecting environmental surfaces and for control of the spread of the so-termed 'disinfectant-resistant' organisms in pharmaceutical cleanrooms. In relation to this, study reports report that species of Pseudomonas, Acinetobacter, Staphylococcus are resistant to biocides in clinical samples (Lambert et al. 2001; Thomas et al. 2005; Kawamura-Sato et al. 2008; Wassenaar et al. 2015) . Moreover, these organisms are considered as objectionable organisms for some nonsterile pharmaceuticals and they have been reported as contaminants of several pharmaceutical products. Hence, there is a possibility of detecting or developing biocide-resistant micro-organisms in pharmaceutical environments where routine cleaning and disinfection is being undertaken. Consequently, if biocide-resistant organisms are allowed to proliferate in the pharmaceutical environment these may cause product contamination if controls are inadequate, and this could lead to production losses or risks to consumer health.
In order to address the potential issue of resistance, US FDA and European Union Good Manufacturing Practice (EU GMP) guidelines recommend that disinfectants be rotated to avoid microbial resistance (a practice that also widens the spectrum of activity, should two different disinfectants with different modes of activity be used). This regulatory expectation notwithstanding, there is no study yet published using cleanroom environmental isolates in relation to disinfectant resistance. As a further control measure, USP <1072> and EU GMP state that monitoring and trending of environmental isolates should be conducted to check the susceptibility pattern of cleanroom isolates to disinfectants as part of the cleanroom disinfection programme (Anon. 2008 (Anon. , 2012 .
It is surprising, in this context, that there is a large volume of publications available which describe the antibiotic resistance and mechanisms in clinical setting and yet there is only a small number of studies available worldwide addressing the mechanisms of biocide resistance in the pharmaceutical facility (Russell and Gould 1988; Russell 1999a; Vijayakumar et al. 2012) . Moreover, very few studies have discussed minimum inhibitory concentration (MIC) values of biocides in relation to pharmaceutical cleanroom isolates .
To address this in this review, we analyse the biocideresistant mechanisms of pharmaceutical environmental isolates and correlated these with the applicable MIC values. Furthermore, we also discuss whether a disinfectant rotation, excluding the need for a sporicidal agent, adds any value for the typical nonsterile pharmaceutical manufacturing facility. The use of sporicidal agents, generally used as a control measure for sterile products' manufacturing, falls outside the scope of this review.
Biocides susceptibility-definition
There is no specific term to describe 'biocide resistance'; however, as per literature, we can consider the definition of 'resistant' in the microbiological context. According to Russell (2001) , an organism is considered to be resistant to a given biocide when it is not inactivated by an in-use concentration of that biocide; or where a biocide concentration that inactivates other organisms but not the organism of concern. Other terms that have been suggested to describe low biocide susceptibility or a decrease in biocide susceptibility of a laboratory culture include 'insusceptibility' or 'reduced susceptibility', 'tolerance' and 'tolerant' (Russell 2001) .
Intrinsic resistance
The phenomenon of resistance is divided into intrinsic and acquired resistance (McDonnell and Russell 1999) . Intrinsic resistance is the naturally greater resistance relating to certain microbial species compared with others. There is a wide range of bacteria that have intrinsic resistance to biocides (Russell 1999a ). These include: (i) spores of Bacillus subtilis, which are less susceptible to biocides than those of Clostridium difficile. Bacillus spores are frequently found as contaminants in pharmaceutical products and in the cleanroom environment. Sandle (2011) reported that the most common species of Bacillus isolated from the pharmaceutical cleanroom are: Bacillus sphaericus, Bacillus cereus and Bacillus fusiformis (Sandle 2011) . (ii) Mycobacterium chelonae strains may show high resistance to glutaraldehyde and Mycobacterium avium intracellulare is generally less sensitive than Mycobacterium tuberculosis to biocides. Occurrence of Mycobacterium species in pharmaceutical environment are less typical than species of Bacillus; however, Park et al. (2014) isolated nontuberculous Mycobacterium from air samples of ISO class 8 cleanroom. (iii) Gram-negative bacteria such as Pseudomonas aeruginosa, Providencia sp. and Proteus sp. are generally less susceptible to biocides because of their cell wall components relative to Grampositive organisms. Gram-negative organism cell walls are composed of a single layer of peptidoglycan and associated efflux pumps, together with an outer membrane associated with lipopolysaccharide and channels. Pseudomonad and related species are the most common contaminants of pharmaceutical water systems, as well as being recovered from cleanroom environments where there are water sources. Apart from this physiological adaptation, nonsusceptibility to biocides is usually encountered as a biofilm, and there is an association of Gram-negative organisms with water system biofilms (Donlan and Costerton 2002) .
Such organisms are additionally among the major contaminants reported in nonsterile pharmaceutical product recalls (Jimenez 2007; Romero-G omez et al. 2008; Sandle 2011; Park et al. 2014 ). (iv) Enterococci which are less sensitive than staphylococci to biocides and antibioticresistant strains of Staphylococcus aureus might show a level of biocide resistance. Personnel may act as a carrier to spread these types of organisms in the production environment (Sandle 2011) , given the association between the shedding of skin detritus and the deposition of Gram-positive cocci that are members of the Micrococcaceae family. Furthermore, 20-30% of the general population are so-termed 'Staph carriers' (Esposito et al. 2018) . Hence, there is a high chance of personnel carrying drug-resistant S. aureus, especially with people who have pimples, impetigo, boils, cellulites, furuncles, carbuncles, scalded skin syndrome and abscess, into the cleanroom.
Acquired resistance
Acquired resistance is where a naturally sensitive microorganism becomes insusceptible to a biocide through one or more mechanism, including mutation, the amplification of an endogenous chromosomal gene, transfer of plasmids and acquisition of genetic determinants (K€ ucken et al. 2000; Bjorland et al. 2001; Russell 2002 Russell , 2004 . In literature, there are several genes involving the resistant character of bacterial isolates to antiseptics, disinfectants and heavy metals. There genes are collectively called as 'biocide resistant genes' (BRGs). For example, plasmidassociated nonsusceptibility in staphylococci has been demonstrated for cationic biocides such as chlorhexidine gluconate and QACs (Kummerle et al. 1996; Russell 1999b) . According to Heinzel's (1998) statement, the term 'acquired resistance' is used if certain strains of a microbial species differ significantly (a certain variance in susceptibility to biocides will naturally occur within one species of microbes) in their susceptibility to biocides compared with the average for this species. In further sections of this review, we discuss the biocide susceptibility testing break point values and the plasmid or genes mediated in biocide resistance mechanisms.
Biocides-susceptibility break point (MIC) test
Microbial susceptibility testing such as Kirby-Bauer disc diffusion, microbroth and macrobroth dilutions were developed for the clinical microbiology laboratory and the aim is to confirm the susceptibility of an organism to a selected empirical antimicrobial agent; or to detect resistance in individual bacteria isolates. The testing methodologies and reference limits are well defined by the Clinical Laboratory Standard Institute (CLSI), USA (Anon. 2015a ). However, with regard to biocide testing, these tests cannot be routinely performed and cannot allow for meaningful conclusions to be drawn (McDonnell and Russell 1999; Russell 1999a) . Until now, there are no established breakpoints for MICs for defined biocides in relation to reduced susceptibility. Moreover, independent reports have proposed different epidemiological cut-off values based on the statistical analysis of MIC values in different test populations (Morrissey et al. 2014) . At the same time, MICs provide a useful reference to biocides when used as preservatives, in which prevention of microbial multiplication and reduction in viability to predetermined levels are more appropriate than inactivation. However, biocides used as antiseptics or topical antimicrobials, and especially those used as disinfectants, are typically used at concentrations well in excess of MIC values.
An understanding of the susceptibility breakpoints of biocides will assist microbiologists to select suitable disinfectants. This will also assist with monitoring the effectiveness of the disinfection programme. Accordingly, USP chapter <1072> and the EU GMP guideline recommended that monitoring of environmental isolates and checking their susceptibility pattern to disinfectants is an important part of cleanroom disinfection programmes, as well as with the wider biocontamination control strategy (Anon. 2008 (Anon. , 2012 . Even though susceptibility breakpoints are recommended, no specific method has been developed and there are no MIC breakpoints provided by the guidelines.
Hence, there is a significant lack of scientific reporting regarding MIC values of typical pharmaceutical cleanroom environmental isolates. For this reason, our review has included cleanroom-associated organisms as incorporated in studies run in the clinical setting. Table 1 explains the worldwide available reports and MIC breakpoints of both clinical and pharmaceutical environmental microbial isolates against commonly used biocides. An important point to consider here is there are + or À two or more dilution variations observed among the various studies reported worldwide. Thus, due to methodologies, variations in MIC values were noted in each study. However, the comparison we make presents the overall picture of the typical MIC values of cleanroom environmental isolates.
MIC values of pharmaceutical environmental bacterial isolates
From the literature of the sensitivity profile to biocidal agents against pharmaceutical cleanroom bacterial isolates, the MIC 90 ranges observed for chlorhexidine gluconate were between 0Á5 and 2 lg ml À1 against various cleanroom bacteria. The lowest range (0Á25-1 lg ml À1 )
MIC value was observed against Staphylococcus sp., while the highest (1-4 lg ml À1 ) was against P. aeruginosa. Benzalkonium chloride showed an MIC 90 range from 2-4 lg ml À1 against all of the bacteria tested. The MIC 90
values of benzalkonium chloride against species of Staphylococcus and Micrococcus was 2 lg ml À1 , whereas P.
aeruginosa and species of Bacillus recorded 4 lg ml À1 as an MIC 90 value. Cetrimide recorded an MIC 90 range between 4 and 8 lg ml À1 against each of the bacteria tested except with isolates of P. aeruginosa where the range was between 32 and 128 lg ml À1 . Through the MIC determination and activity spectrum classification of various disinfectants, it is possible to establish the appropriate disinfection concentrations for a facility sanitization programme. 
MIC values of pharmaceutical environmental fungal isolates
The activity of biocides against fungal micro-organisms is not as well documented as the activity against bacteria. In general, fungi are more resistant to biocides than nonsporulating bacteria, with Day et al. (2009) finding that moulds are generally more resistant than yeasts. Only a few studies are available for describing the lethal concentrations of antiseptics and disinfectants towards yeasts and moulds (Wallhauser 1984; Day et al. 2009; Vijayakumar et al. 2012) . reported a large series study of the MIC of biocides in relation to cleanroom fungal isolates. The authors concluded that the MICs of chlorhexidine, benzalkonium chloride and cetrimide were not more than 16 lg ml À1 against hyaline fungi, while the MIC range of biguanides and QACs against dematiaceous fungi ranged from 8 to 16 lg ml À1 . No previous published studies have examined the MIC values of biguanides and QACs against cleanroom fungi. Therefore, the comparison of MIC results with other fungal reports is difficult.
Genes involving biocide resistance
Acquired resistance is a notable concern and there are several genes involved in building the resistant character of bacterial isolates to biocides. Genes conferring reduced susceptibility to QACs (such as benzalkonium chloride, cetrimide) are called qac (Wassenaar et al. 2015) . Different classes of qac gene families exist, and these are highly conserved and typically composed of 100 amino acids in length and contain two trans-membrane domains. These bacterial genes encode efflux pumps, which are capable of expelling many QAC structures from bacterial cells. This serves to decrease the susceptibility of bacteria to QAC disinfectants. Qac genes can be horizontally transferred via plasmids to other bacteria. This process can occur at the same time as the transfer of other antibiotic-resistant genes (Jennings et al. 2015) . The first described genetic determinant of resistance to antiseptics was the qacA gene found in an S. aureus plasmid pSK1 and b-lactamase/heavy metal resistance plasmids (Gillespie et al. 1986; Lyon and Skurray 1987) . Since then, a range of various qac genes have been described. The qac genes are relatively widely spread among clinical and environmental bacteria, and it is evident that their distribution is generally linked with particular bacterial species (Bischoff et al. 2012; Babaei et al. 2015) . Among Gram-positive bacteria, the qac genes clearly predominate in staphylococci, in which the qacA/ B genes were most frequently reported followed by the qacC/D genes (Longtin et al. 2011; Zmantar et al. 2012) . Other qac genes, such as qacG, qacH and qacJ, have been less frequently observed (Ye et al. 2012) . Besides staphylococci, the qac genes were also detected in enterococci. For instance, the qacA/B genes and the most recently identified qac gene, qacZ, were recently found in Enterococcus faecalis (Braga et al. 2011; Bischoff et al. 2012) . In contrast, the qacE gene (including its attenuated variant qacED1) is widely found in Gram-negative bacteria, mainly in the Enterobacteriaceae family and with Pseudomonas species. The gene is also present in a range of other species such as Aeromonas sp., Vibrio sp., Acinetobacter sp. (Chang et al. 2007; Wang et al. 2008; Mak et al. 2009 ) qacE and qacΔE genes mediate resistance by a proton pump, and both confer bacterial resistance to quaternary ammonium disinfectants (e.g. benzalkonium chloride), biguanide compounds (such as chlorhexidine) and hydrazones. Although less common, other qacH and qacF genes have also been found in Gram-negative bacteria. The qacH gene was most often described in Enterobacteriaceae (Borgianni et al. 2011; Wannaprasat et al. 2011) .
Prevalence of BRGs worldwide
Worldwide differences in the presence of qac genes among bacterial populations can be observed by analysing various clinical reports (refer Table 2 ); however, similar types of studies are not available for pharmaceutical environmental bacterial isolates. With fungi, there is no evidence of acquired biocide resistance linking the presence of plasmids and other transferable genetic materials to the ability of a fungal cell to acquire resistance to fungistatic or fungicidal agents . However, the development of acquired resistance in fungi has not been widely studied.
By comparing worldwide reports, the prevalence of BRGs varying among different organisms and their sources can be considered. Our review revealed that qacA/B is commonly present in the Staphylococcus species. Moreover, we established that other Gram-negative organisms, such as genus of Klebsiella and Pseudomonas, are carrying the qacE and cepA genes are emerging. Pharmaceutical microbiologists, in noting this finding, should consider the need to conduct such BRG prevalence studies in relation to environmental isolates, in order to form a picture about changing susceptibility trends.
Presence of BRGs vs MICs
Many reports on emerging bacterial resistance to biocides are based on the determination of MICs. Using MICs to measure bacterial resistance is useful since much higher concentrations of biocides are used in practice and, therefore, failing to achieve a reduction in the bacterial numbers (i.e. lethality) because of elevated MICs is unlikely (Russell 2000) . Indeed, some studies have shown that bacterial strains showing a significant increase in MICs to some biocides were nevertheless susceptible to higher (in use) concentrations of the same biocides (Thomas et al. 2005; Naparstek et al. 2012; Azadpour et al. 2015; Babaei et al. 2015) . Thus, here, we reviewed recent literatures and analyse the correlation between reduced susceptibility and the harbouring BRG with environmental isolates (Table 3) .
In the United Kingdom, two studies were conducted by Abuzaid and colleagues. It was reported that Klebsiella pneumoniae showed a reduced susceptibility to biocides due to the presence of qacΔE1 and cepA genes (Abuzaid et al. 2012; Abuzaid and Amyes 2015) . In contrast, Azadpour et al. (2015) reported that no significant association of biocides resistance existed with the presence of qacEΔ1 and cepA genes in K. pneumoniae; and in a separate study, Naparstek et al. (2012) did not find any correlation between chlorhexidine susceptibility and cepA gene expression (Naparstek et al. 2012) . A large series study conducted using 122 isolates of multidrug-resistant Acinetobacter baumannii showed that no significant difference was observed in the MIC of biocides and the presence or absence of the qacE gene (Babaei et al. 2015) . Interestingly another study by Liu et al. (2017) reported that carbapenem-resistant A. baumannii strains harbouring qacE displayed a higher MIC (64 lg ml À1 ) for benzalkonium chloride; at the same time qacEΔ1 genes were found to exert no significant impact on reduced susceptibility. This is similar to the findings of Romão et al. (2011) who reported that qacEΔ1 does not play an important role in biocide resistance in P. aeruginosa clinical isolates (Romão et al. 2011) . A study by Vali et al. (2017) reported that that presence of qacA genes in MRSA may not be significant in reducing susceptibility or prompting higher MBC to chlorhexidine. Overall, there are reports indicating that the presence of BRGs causes reduced susceptibility values. However, further studies are required to confirm these findings. By comparing available literature, many reports showed there are no significant findings observed to link the presence of BRGs to reduced susceptibility. Consequently, the distribution and transmission of bacterial resistance to biocides are likely to be affected and constrained by biological, physical and socio-economic factors and these will vary among different countries, regions and communities. The reason for such differences may be due to variations with the study population; patterns of biocideresistant genes and difference with the MIC analysis of different groups of biocides. According to this comparison, a large-scale study, based on a uniform test method, is required for each specific bacterium in order to confirm the reduced susceptibility and the presence of BRGs. While there are several studies available in clinical settings, these are not sufficiently suitable to allow for a conclusion to be drawn in the pharmaceutical context. Thus, there is no straightforward way to compare pharmaceutical isolates and the possibility remains of resistance developing in the context of low disinfectant concentrations and in relation to the varying patterns of disinfectant rotation as practiced across different facilities.
Is disinfectant rotation really needed?
A final point to discuss is disinfectant rotation, which is central to the disinfectant programme and a requirement of many regulatory bodies. The earliest request for rotation came from Europe and the EU GMP Guide continues to state that: 'where disinfectants are used, more than one type should be employed' (Annex 1) (Anon. 2008 ). This statement is normally interpreted as a requirement for two different types of disinfectant to be used and rotated. Both the Japanese sterile products' manufacturing guidance (Anon. 2006 ) and those of the FDA (Anon. 2004) describe the use of sporicidal disinfectants to be used in addition to non-sporicidal disinfectants as part of a cleanroom disinfectant programme. Whether these infer one disinfectant being alternated with another or one or more than one disinfectant with a sporicidal product is not always clear. A clearer signal is within the Parenteral Drug Association Technical Report 70, which states 'most firms use a system whereby a disinfectant is rotated with a sporicide to more effectively reduce the bioburden levels' and 'all rotation systems should be evaluated' (Anon. 2015b) . The USP <1072>, in contrast, is less exacting and poses some questions about the scientific need for rotation.
However, the document does state that 'rotation of an effective disinfectant with a sporicide is encouraged'. One argument for rotating two disinfectants (where one disinfectant is periodically replaced by another that has a different mode of action) is to reduce the possibility of resistant strains of micro-organisms developing (Anon. 2012) . This recommendation was derived from clinical experience with antibiotics and it does not, as the paucity of literature indicates, apply directly to disinfectants, antiseptics and sanitizers. There has been considerable debate as to whether biocide resistance and antibiotic resistance are in any way linked. On first consideration, these two groups of antibacterial agents are relatively dissimilar. Additionally, antibiotics, as selectively toxic agents suitable for administration to patients, have a specific target site within a bacterial cell. In contrast, biocides (antiseptics, disinfectants and preservatives) have multiple cellular target sites. The reported resistance to common disinfectants does not occur at in-use concentrations and 'resistance' to the chemical is more accurately considered as reduced susceptibility. However, no study has been reported that assesses whether a biocide resistance trend in pharmaceutical environmental set-ups occurs; hence this statement is need to reconsideration. When selecting disinfectants with different modes of activity, the regulatory expectation is that one of the selected disinfectants is a sporicide in order to combat any populations of bacterial spores, together with their vegetative clones, present in pharmaceutical processing areas (Sandle 2016) . With regard to the frequency of rotation between the two selected biocides, this tends to be based on the environmental monitoring data. Given that environmental monitoring data should be reviewed for trends on a regular basis, this allows the frequency of cleaning and disinfection to be based on risk assessment and this approach generally meets regulatory expectations. At the same time checking the MIC of biocides against cleanroom environmental isolates will be helpful for monitoring the presence or absence of any resistant effect. This approach of monitoring environmental isolates and examining their susceptibility pattern to disinfectants, is something we consider as very important for cleanroom disinfection programme. When using environmental isolates, variations in the CLSI methods may be required and resultant protocols will need to take account of culture preparation and culture age, and recommendations for specific culture media.
Conclusion
In conclusion, based on the guidance contained in USP <1072> and European GMP, the periodic monitoring of environmental isolates and the assessment of their susceptibility pattern to disinfectants, forms an essential part of the cleanroom disinfection programme and the wider biocontamination control strategy. While disinfectants are often subject to efficacy testing (commonly undertaken through in-use dilution methods or surface ('coupon') tests) against a standard panel of test organisms, this approach does not necessarily provide the complete picture. A key concern, highlighted in this paper, is with how to achieve an assessment of microbial susceptibility patterns, especially since recoveries from the environmental monitoring programme cannot provide sufficient information about resistance patterns. Recoveries of one species, from environmental monitoring, over another may relate to resistance or, alternatively, it may reflect other factors, such as variabilities with cleaning and disinfection; limitations with sampling methods; equipment faults; air handling system breakdown; the introduction of material into the cleanroom in an uncontrolled way and so on.
Hence, there is the need for an alternative means of assessment to meet compendia and regulatory expectations. We recommend that pharmaceutical organizations adopt test methodologies to examine the MICs of common cleanroom biocides against the types of cleanroom environmental isolates found in facilities. The types of organisms for such challenges will vary, given the differences in geography and the nature of pharmaceutical operations. At the same time, we hope that further studies undertaken on the distribution of biocide-resistant genes draw upon some data pertaining to pharmaceutical environments. These different measures will contribute to a better understanding about biocide-resistant mechanisms, contextualize the potential risks of certain organisms to cleanroom environments and provide scientific evidence to support (or contradict) the need for disinfectant rotation.
